^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Fovista (pegpleranib)

    i
    Associations
    News

    Trials

    Company:
    Astellas, Roche
    Drug class:
    PDGFR inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab (NCT02859441)
    Phase 1/2
    National Eye Institute (NEI)
    Completed
    Last update posted :
    11/01/2021
    Initiation :
    01/23/2017
    Primary completion :
    07/09/2019
    Completion :
    07/09/2019
    VHL
    |
    VHL mutation
    |
    Fovista (pegpleranib) • Lucentis (ranibizumab)